“Our diagnostics portfolio with the with the addition of Exact, the VBP impact in China subsiding a little bit is now a 7% to 8% kind of range that we think about.”

In context

“s ago. it is probably only I think I looked at this as only like 5 healthcare companies with sales over 30 billion that are growing at least 7%. So I think I think we have a differentiated portfolio here, a very resilient portfolio. And I think, as I said, the strategy here of what we have been doing over the last couple quarters to get us in back into that, into that, 7% top line growth rate. I think it is really driven, Travis, by looking at the portfolio and then the-- if I look at, you know, the 4 segments, again, I am not providing 2027 guidance, but when I look at you know, each 1 of them and their ranges, you know, nutrition, you know, has been a 2% to 4% grower, and I think that is probably, as we think about it going forward, that is probably the right range to be thinking about. Our diagnostics portfolio with the with the addition of Exact, the VBP impact in China subsiding a little bit is now a 7% to 8% kind of range that we think about. Our EPD business has reliably done this for, like, 5 years, like, 7% to 9%. And med tech, you know, we view as kind of an 8% to 10% grower. So, you know, the low end of that range is around 6.5%. The high end is around 8%. So I think 7 is a is a is a is a pretty sustainable kinda growth rate going forward. So and that is what we are that is what we target high single digit, double digit EPS growth. And I think we are well positioned executing what we are executing in the second half And the portfolio we have, I think I think the sustainability of that 7%. And then obviously all the pipeline. I mean, we have got programs that we are gonna start in Q4, at least from a trial perspective, that are gonna start to deliver contributions in 2029-2030. So, yeah, we are thinking about 27, for sure,”